Publications
Articles
High-throughput flow cytometry data normalization for clinical trials
(2014). Cytometry A, 85 (3), 277-86. http://dx.doi.org/10.1002/cyto.a.22433, PMID: 24382714, PMCID: PMC3992339
Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, Asare D, De Rosa SC, Self S, Gottardo R
[Reprint] [PubMed]
[Citation View]
Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, Asare D, De Rosa SC, Self S, Gottardo R (2014). High-throughput flow cytometry data normalization for clinical trials. Cytometry A, 85 (3), 277-86.
Rituximab for the Treatment of Relapses in antineutrophil cytoplasmic antibody-associated vasculitis
(2014). Arthritis Rheumatol, 66 (11), 3151-59. http://dx.doi.org/10.1002/art.38788, PMID: 25047592, PMCID: PMC4229846
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villareal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
[Reprint] [PubMed]
[Citation View]
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villareal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group (2014). Rituximab for the Treatment of Relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol, 66 (11), 3151-59.
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
(2014). J Allergy Clin Immunol, 133 (2), 468-75. http://dx.doi.org/10.1016/j.jaci.2013.11.007, PMID: 24361082, PMCID: PMC3960331
Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW
[Reprint] [PubMed]
[Citation View]
Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW (2014). Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol, 133 (2), 468-75.
Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
(2014). Arthritis & Rheumatology, 66 (11), 3096-104. http://dx.doi.org/10.1002/art.38790, PMID: 25403681, PMCID: PMC4528976
The ACCESS Trial Group
[Reprint] [PubMed]
[Citation View]
The ACCESS Trial Group (2014). Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis & Rheumatology, 66 (11), 3096-104.
Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression
(2014). Am J Transplant, 14 (7), 1599-1611. http://dx.doi.org/10.1111/ajt.12731, PMID: 24903438, PMCID: PMC4228952
Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman Sl, Zorn E, Tolkoff-Rubin N, Preffer F, Crisalli K, Gao B, Wong W, Morris H, LoCascio SA, Sayre P, Shonts B, Williams WW, Colvin RB, Smith R-N, Sykes M, Cosimi AB.
[Reprint] [PubMed]
[Citation View]
Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman Sl, Zorn E, Tolkoff-Rubin N, Preffer F, Crisalli K, Gao B, Wong W, Morris H, LoCascio SA, Sayre P, Shonts B, Williams WW, Colvin RB, Smith R-N, Sykes M, Cosimi AB. (2014). Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant, 14 (7), 1599-1611.
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: Immunologic effects and efficacy in NOD mice
(2013). PLoS One, 8 (2), e54712. http://dx.doi.org/10.1371/journal.pone.0054712, PMID: 23405091, PMCID: PMC3566105
Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, Nepom G, Ehlers M, Staeva T, Garren H, Steinman L, Chan AC, von Herrath M
[Reprint] [PubMed]
[Citation View]
Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, Nepom G, Ehlers M, Staeva T, Garren H, Steinman L, Chan AC, von Herrath M (2013). Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: Immunologic effects and efficacy in NOD mice. PLoS One, 8 (2), e54712.
Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data
(2013). J Immunol Methods, 391 (1-2), 14-21. http://dx.doi.org/10.1016/j.jim.2013.02.002, PMID: 23428915
Emerson R, Sherwood A, Desmarais C, Malhotra S, Phippard D, Robins H
[Reprint] [PubMed]
[Citation View]
Emerson R, Sherwood A, Desmarais C, Malhotra S, Phippard D, Robins H (2013). Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data. J Immunol Methods, 391 (1-2), 14-21.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
(2013). Diabetes, 62 (11), 3766-74. http://dx.doi.org/10.2337/db13-0345, PMID: 23835333, PMCID: PMC3806618
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, the AbATE Study Team
[Reprint] [PubMed]
[Citation View]
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, the AbATE Study Team (2013). Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes, 62 (11), 3766-74.
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
(2013). N Engl J Med, 369 (5), 417-27. http://dx.doi.org/10.1056/NEJMoa1213277, PMID: 23902481
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH for the RAVE-ITN Research Group
[Reprint] [PubMed]
[Citation View]
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH for the RAVE-ITN Research Group (2013). Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med, 369 (5), 417-27.
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial
(2013). Lancet Diabetes Endocrinol, 1 (4), 306-16. http://dx.doi.org/10.1016/S2213-8587(13)70065-2, PMID: 24622416
Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team
[Reprint] [PubMed]
[Citation View]
Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team (2013). Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol, 1 (4), 306-16.
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
(2013). Lancet Diabetes Endocrinol, 1 (4), 284-94. http://dx.doi.org/10.1016/S2213-8587(13)70111-6, PMID: 24622414, PMCID: PMC3957186
Rigby MR, DiMeglio LA, Rendell MS, Felner E, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, Immune Tolerance Network T1DAL Study Team
[Reprint] [PubMed]
[Citation View]
Rigby MR, DiMeglio LA, Rendell MS, Felner E, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, Immune Tolerance Network T1DAL Study Team (2013). Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol, 1 (4), 284-94.
Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
(2013). Arthritis Rheum, 65 (9), 2441-9. http://dx.doi.org/10.1002/art.38044, PMID: 23754238, PMCID: PMC4949954
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH, for the Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
[Reprint] [PubMed]
[Citation View]
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH, for the Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group (2013). Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Rheum, 65 (9), 2441-9.
Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity
(2013). Diabetes Care, 36 (8), 2266-70. http://dx.doi.org/10.2337/dc12-2245, PMID: 23423694, PMCID: PMC3714529
Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK
[Reprint] [PubMed]
[Citation View]
Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK (2013). Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care, 36 (8), 2266-70.
Pre-existing epithelial diversity in normal human livers: A tissue-tethered cytometric analysis in portal/periportal epithelial cells
(2013). Hepatology, 57 (4), 1632-43. http://dx.doi.org/10.1002/hep.26131, PMID: 23150208, PMCID: PMC3612393
Isse K, Lesniak A, Grama K, Maier J, Specht S, Castillo-Rama M, Lunz J, Roysam B, Michalopoulos G, Demetris AJ
[Reprint] [PubMed]
[Citation View]
Isse K, Lesniak A, Grama K, Maier J, Specht S, Castillo-Rama M, Lunz J, Roysam B, Michalopoulos G, Demetris AJ (2013). Pre-existing epithelial diversity in normal human livers: A tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology, 57 (4), 1632-43.
Ancillary study management systems: a review of needs
(2013). BMC Med Inform Decis Mak, 13 (5), 1-17. http://dx.doi.org/10.1186/1472-6947-13-5, PMID: 23294514, PMCID: PMC3564696
Nelson EK, Piehler B, Rauch A, Ramsay S, Holman D, Asare S, Asare A, Igra M
[Reprint] [PubMed]
[Citation View]
Nelson EK, Piehler B, Rauch A, Ramsay S, Holman D, Asare S, Asare A, Igra M (2013). Ancillary study management systems: a review of needs. BMC Med Inform Decis Mak, 13 (5), 1-17.
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants
(2012). JAMA, 307 (3), 283-93. http://dx.doi.org/10.1001/jama.2011.2014, PMID: 22253395
Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK
[Reprint] [PubMed]
[Citation View]
Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK (2012). Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA, 307 (3), 283-93.
Circulating angiopoietin-2 as a biomarker in ANCA-associated Vasculitis
(2012). PLoS One, 7 (1), e30197. http://dx.doi.org/10.1371/journal.pone.0030197, PMID: 22279570, PMCID: 3261176
Monach PA, Kumpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Ikle D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA
[Reprint] [PubMed]
[Citation View]
Monach PA, Kumpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Ikle D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA (2012). Circulating angiopoietin-2 as a biomarker in ANCA-associated Vasculitis. PLoS One, 7 (1), e30197.
Randomized controlled trial of atorvastatin in clinically isolated syndrome
(2012). Neurology, 78 (15), 1171-8. http://dx.doi.org/10.1212/WNL.0b013e31824f7fdd, PMID: 22459680, PMCID: PMC3320055
Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS, ITN020AI Study Management Team, ITN STAyCIS Study Group
[Reprint] [PubMed]
[Citation View]
Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS, ITN020AI Study Management Team, ITN STAyCIS Study Group (2012). Randomized controlled trial of atorvastatin in clinically isolated syndrome. Neurology, 78 (15), 1171-8.
Rapamycin/IL-2 combination therapy in Type 1 Diabetes
(2012). Diabetes, 61 (9), 2340-8. , PMID: 22721971, PMCID: PMC3425404
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network
[Reprint] [PubMed]
[Citation View]
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network (2012). Rapamycin/IL-2 combination therapy in Type 1 Diabetes. Diabetes, 61 (9), 2340-8.
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes
(2012). J Immunol Methods, 384 (1-2), 25-31. , PMID: 22759401
Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, Togias A, Phippard D, Turka LA, Hansel TT, Durham SR, Wurtzen PA
[Reprint] [PubMed]
[Citation View]
Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, Togias A, Phippard D, Turka LA, Hansel TT, Durham SR, Wurtzen PA (2012). Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods, 384 (1-2), 25-31.
Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study
(2012). J Allergy Clin Immunol, 131 (1), 135-143. , PMID: 23174658
Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G
[Reprint] [PubMed]
[Citation View]
Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G (2012). Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study. J Allergy Clin Immunol, 131 (1), 135-143.
QUAliFiER: An automated pipeline for quality assessment of gated flow cytometry data
(2012). BMC Bioinformatics, Sep (13), 252. , PMID: 23020243, PMCID: 3499158
Finak G, Jiang W, Pardo J, Asare A, Gottardo R
[PubMed]
[Citation View]
Finak G, Jiang W, Pardo J, Asare A, Gottardo R (2012). QUAliFiER: An automated pipeline for quality assessment of gated flow cytometry data. BMC Bioinformatics, Sep (13), 252.
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
(2012). Allergy, 62 (2), 217-26. http://dx.doi.org/10.1111/j.1398-9995.2011.02745.x, PMID: 22077562
Shamji MH, Ljorring C, Francis JN, Calderon MA, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR
[Reprint] [PubMed]
[Citation View]
Shamji MH, Ljorring C, Francis JN, Calderon MA, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR (2012). Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy, 62 (2), 217-26.
Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients
(2012). Am J Transplant., 12 (3), 640-8. http://dx.doi.org/10.1111/j.1600-6143.2011.03869, PMID: 22151236, PMCID: PMC3374729
Haynes LD, Jankowska-Gan E, Sheka A, Keller MR, Hernandez-Fuentes MP, Lechler RI, Seyfert-Margolis V, Turka LA, Newell KA, Burlingham WJ
[Reprint] [PubMed]
[Citation View]
Haynes LD, Jankowska-Gan E, Sheka A, Keller MR, Hernandez-Fuentes MP, Lechler RI, Seyfert-Margolis V, Turka LA, Newell KA, Burlingham WJ (2012). Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant., 12 (3), 640-8.
Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies
(2011). J Allergy Clin Immunol, 127 (2), 509-16. http://dx.doi.org/10.1016/j.jaci.2010.12.1080, PMID: 21281875
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham, SR
[Reprint] [PubMed]
[Citation View]
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham, SR (2011). Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol, 127 (2), 509-16.
Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts
(2011). Am J Transplant, 11 (7), 1464-77. http://dx.doi.org/10.1111/j.1600-6143.2011.03572.x, PMID: 21668634, PMCID: PMC3128680
Farris AB, Taheri D, Kawai T, Fazlollahi L, Wong W, Tolkoff-Rubin N, Spitzer TR, Iafrate AJ, Preffer FI, LoCascio SA, Sprangers B, Saidman S, Smith RN, Cosimi AB, Sykes M, Sachs DH, Colvin RB
[Reprint] [PubMed]
[Citation View]
Farris AB, Taheri D, Kawai T, Fazlollahi L, Wong W, Tolkoff-Rubin N, Spitzer TR, Iafrate AJ, Preffer FI, LoCascio SA, Sprangers B, Saidman S, Smith RN, Cosimi AB, Sykes M, Sachs DH, Colvin RB (2011). Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant, 11 (7), 1464-77.
Increased frequencies of myelin oligodendrocyte glycoprotein/MHC Class II-binding CD4 cells in patients with multiple sclerosis
(2011). J Immunol, 187 (2), 1039-46. http://dx.doi.org/10.4049/jimmunol.1001543, PMID: 21653833, PMCID: PMC3131477
Radassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, Nepom GT, Kwok WW, Hafler DA
[Reprint] [PubMed]
[Citation View]
Radassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, Nepom GT, Kwok WW, Hafler DA (2011). Increased frequencies of myelin oligodendrocyte glycoprotein/MHC Class II-binding CD4 cells in patients with multiple sclerosis. J Immunol, 187 (2), 1039-46.
Design of the Rituximab in ANCA-associated Vasculitis (RAVE) Trial
(2011). The Open Arthritis Journal, 4 (1), 1-18.
Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, Kallenberg CGM, St. Clair EW, Ding L, Webber L, Mokhtarani M, Tchao NK, Sayre PH, Seyfert-Margolis V, Ikle D, Brunetta P, Zhang D, Sejismundo L, Mueller M, Stone JH
[Reprint]
[Citation View]
Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, Kallenberg CGM, St. Clair EW, Ding L, Webber L, Mokhtarani M, Tchao NK, Sayre PH, Seyfert-Margolis V, Ikle D, Brunetta P, Zhang D, Sejismundo L, Mueller M, Stone JH (2011). Design of the Rituximab in ANCA-associated Vasculitis (RAVE) Trial. The Open Arthritis Journal, 4 (1), 1-18.
Circulating markers of vascular injury and angiogenesis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
(2011). Arthritis Rheum, 36 (12), 3988-97. http://dx.doi.org/10.1002/art.30615, PMID: 21953143, PMCID: PMC3227746
Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA
[Reprint] [PubMed]
[Citation View]
Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA (2011). Circulating markers of vascular injury and angiogenesis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheum, 36 (12), 3988-97.
Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction
(2011). Semin Immunol, 23 (4), 273-81. http://dx.doi.org/10.1016/j.smim.2011.05.001, PMID: 21705229, PMCID: PMC3201788
Strober S, Spitzer TR, Lowsky R, Sykes M
[Reprint] [PubMed]
[Citation View]
Strober S, Spitzer TR, Lowsky R, Sykes M (2011). Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol, 23 (4), 273-81.
Immuno-intervention for the induction of transplantation tolerance through mixed chimerism
(2011). Semin Immunol, 23 (3), 165-73. http://dx.doi.org/10.1016/j.smim.2011.07.001, PMID: 21839648, PMCID: PMC3178004
Sachs DH, Sykes M, Kawai T, Cosimi AB
[Reprint] [PubMed]
[Citation View]
Sachs DH, Sykes M, Kawai T, Cosimi AB (2011). Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol, 23 (3), 165-73.
Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation
(2011). Am J Transplant, 11 (6), 1236-47. http://dx.doi.org/10.1111/j.1600-6143.2011.03566.x, PMID: 21645255, PMCID: PMC3140222
Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, LoCascio SA, Morokata T, Dey BR, Tolkoff-Rubin NT, Preffer F, Bonnefoix T, Kattleman K, Spitzer TR, Sachs DH, Sykes M
[Reprint] [PubMed]
[Citation View]
Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, LoCascio SA, Morokata T, Dey BR, Tolkoff-Rubin NT, Preffer F, Bonnefoix T, Kattleman K, Spitzer TR, Sachs DH, Sykes M (2011). Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant, 11 (6), 1236-47.
Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease
(2011). Transplantation, 91 (6), 672-6. http://dx.doi.org/10.1097/TP.0b013e31820a3068, PMID: 21217460, PMCID: PMC3232059
Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, Cosimi AB
[Reprint] [PubMed]
[Citation View]
Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, Cosimi AB (2011). Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation, 91 (6), 672-6.
Per-channel basis normalization methods for flow cytometry data
(2010). Cytometry A, 77 (2), 121-31. http://dx.doi.org/10.1002/cyto.a.20823, PMID: 19899135, PMCID: PMC3648208
Hahne F, Khodabakhshi AH, Bashashati A, Wong CJ, Gascoyne RD, Weng AP, Seyfert-Margolis V, Bourcier K, Asare A, Lumley T, Gentleman R, Brinkman RR
[Reprint] [PubMed]
[Citation View]
Hahne F, Khodabakhshi AH, Bashashati A, Wong CJ, Gascoyne RD, Weng AP, Seyfert-Margolis V, Bourcier K, Asare A, Lumley T, Gentleman R, Brinkman RR (2010). Per-channel basis normalization methods for flow cytometry data. Cytometry A, 77 (2), 121-31.
Identification of a B cell signature associated with renal transplant tolerance in humans
(2010). J Clin Invest, 120 (6), 1836-47. http://dx.doi.org/10.1172/JCI39933, PMID: 20501946, PMCID: PMC2877933
Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL
[Reprint] [PubMed]
[Citation View]
Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL (2010). Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest, 120 (6), 1836-47.
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans
(2010). J Clin Invest, 120 (6), 1848-61. http://dx.doi.org/10.1172/JCI39922, PMID: 20501943, PMCID: PMC2877932
Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI
[Reprint] [PubMed]
[Citation View]
Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI (2010). Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest, 120 (6), 1848-61.
Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy
(2010). J Autoimmun, 34 (4), 408-15. http://dx.doi.org/10.1016/j.jaut.2009.10.005, PMID: 19931408, PMCID: PMC2860016
Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P
[Reprint] [PubMed]
[Citation View]
Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P (2010). Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun, 34 (4), 408-15.
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
(2010). New Eng J Med, 363 (3), 221-32. http://dx.doi.org/10.1056/NEJMoa090990, PMID: 20647199, PMCID: PMC3137658
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group
[Reprint] [PubMed]
[Citation View]
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010). Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New Eng J Med, 363 (3), 221-32.
Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance
(2010). Transplantation, 90 (12), 1607-15. http://dx.doi.org/10.1097/TP.0b013e3181ffbaff, PMID: 21085064, PMCID: PMC3059844
LoCascio SA, Morokata T, Chittenden M, Preffer FI, Dombkowski DM, Andreola G, Crisalli K, Kawai T, Saidman Sl, Spitzer TR, Tolkoff-Rubin N, Cosimi BA, Sachs DH, Sykes M
[Reprint] [PubMed]
[Citation View]
LoCascio SA, Morokata T, Chittenden M, Preffer FI, Dombkowski DM, Andreola G, Crisalli K, Kawai T, Saidman Sl, Spitzer TR, Tolkoff-Rubin N, Cosimi BA, Sachs DH, Sykes M (2010). Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation, 90 (12), 1607-15.
Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients
(2009). Cytometry B Clin Cytom, 72 (2), 69-78. http://dx.doi.org/10.1002/cyto.b.20446, PMID: 18690669
Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert-Margolis V, Wallace PK
[Reprint] [PubMed]
[Citation View]
Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert-Margolis V, Wallace PK (2009). Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom, 72 (2), 69-78.
Power enhancement via multivariate outlier testing with gene expression arrays
(2009). Bioinformatics, 25 (1), 48-53. http://dx.doi.org/10.1093/bioinformatics/btn591, PMID: 19015138, PMCID: PMC2638936
Asare A, Gao Z, Carey VJ, Wang R, Seyfert-Margolis V
[Reprint] [PubMed]
[Citation View]
Asare A, Gao Z, Carey VJ, Wang R, Seyfert-Margolis V (2009). Power enhancement via multivariate outlier testing with gene expression arrays. Bioinformatics, 25 (1), 48-53.
Representing and Reasoning with Temporal Constraints in Clinical Trials Using Semantic Technologies
(2009). Biomedical Engineering Systems and Technologies Springer Berlin Heidelberg, Apr (78), Suppl 1:S77-85. http://dx.doi.org/10.1016/j.ijmedinf.2008.07.013, PMID: 18789876
Shankar RD, Martins SB, O'Connor MJ, Parrish DB, Das AK
[Reprint] [PubMed]
[Citation View]
Shankar RD, Martins SB, O'Connor MJ, Parrish DB, Das AK (2009). Representing and Reasoning with Temporal Constraints in Clinical Trials Using Semantic Technologies. Biomedical Engineering Systems and Technologies Springer Berlin Heidelberg, Apr (78), Suppl 1:S77-85.
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring
(2009). Am J Transplant, 9 (5), 1087-98. http://dx.doi.org/10.1111/j.1600-6143.2009.02581.x, PMID: 19344431
Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW
[Reprint] [PubMed]
[Citation View]
Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW (2009). Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant, 9 (5), 1087-98.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years
(2009). Clin Immunol, 132 (2), 166-73. http://dx.doi.org/10.1016/j.clim.2009.04.007, PMID: 19443276, PMCID: PMC2735402
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, ImmuneTolerance Network ITN007AI Study Group
[Reprint] [PubMed]
[Citation View]
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, ImmuneTolerance Network ITN007AI Study Group (2009). Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol, 132 (2), 166-73.
Single nucleotide transcription factor 7-like 2 (TCF7L2) gene polymorphisms in antiislet autoantibody-negative patients at onset of diabetes
(2009). J Clin Endocrinol Metab, 94 (2), 504-10. http://dx.doi.org/10.1210/jc.2007-2694, PMID: 19050058, PMCID: PMC2646512
Yu J, Steck AK, Babu S, Yu L, Miao D, McFann K, Hutton J, Eisenbarth GS, Klingensmith G
[Reprint] [PubMed]
[Citation View]
Yu J, Steck AK, Babu S, Yu L, Miao D, McFann K, Hutton J, Eisenbarth GS, Klingensmith G (2009). Single nucleotide transcription factor 7-like 2 (TCF7L2) gene polymorphisms in antiislet autoantibody-negative patients at onset of diabetes. J Clin Endocrinol Metab, 94 (2), 504-10.
Murine high specificity/sensitivity competitive europium insulin autoantibody assay
(2009). Diabetes Technol Ther, 11 (4), 227-33. http://dx.doi.org/10.1089/dia.2008.0072, PMID: 19344197, PMCID: PMC2903340
Babaya N, Liu E, Miao D, Li M, Yu L, Eisenbarth GS
[Reprint] [PubMed]
[Citation View]
Babaya N, Liu E, Miao D, Li M, Yu L, Eisenbarth GS (2009). Murine high specificity/sensitivity competitive europium insulin autoantibody assay. Diabetes Technol Ther, 11 (4), 227-33.
Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays
(2009). BMC Immunol, 28 (10), 52. http://dx.doi.org/10.1186/1471-2172-10-52, PMID: 19785746, PMCID: PMC2761376
de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V
[Reprint] [PubMed]
[Citation View]
de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V (2009). Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol, 28 (10), 52.
B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans
(2009). Am J Transplant, 9 (9), 2126-35. http://dx.doi.org/10.1111/j.1600-6143.2009.02738.x, PMID: 19624570, PMCID: PMC2837587
Porcheray F, Wong W, Saidman Sl, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E
[Reprint] [PubMed]
[Citation View]
Porcheray F, Wong W, Saidman Sl, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E (2009). B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant, 9 (9), 2126-35.
HLA-Mismatched renal transplantation without maintenance immunosuppression
(2008). N Engl J Med, 358 (4), 353-61. http://dx.doi.org/10.1056/NEJMoa071074, PMID: 18216355, PMCID: PMC2819046
Kawai, T, Cosimi AB, Spitzer TR, Tolkoff-Rubin, N, Suthanthiran M, Saidman Sl, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DSC, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH
[Reprint] [PubMed]
[Citation View]
Kawai, T, Cosimi AB, Spitzer TR, Tolkoff-Rubin, N, Suthanthiran M, Saidman Sl, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DSC, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH (2008). HLA-Mismatched renal transplantation without maintenance immunosuppression. N Engl J Med, 358 (4), 353-61.
CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial
(2008). Neurology, 71 (12), 917-24. http://dx.doi.org/10.1212/01.wnl.0000325915.00112.61, PMID: 18794494
Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CRG, Rusche JR, Khoury SJ
[Reprint] [PubMed]
[Citation View]
Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CRG, Rusche JR, Khoury SJ (2008). CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology, 71 (12), 917-24.